2 months ago
ATAI
AnalystsEddie HickmanEddie Hickman's Stock Forecasts
AnalystsEddie Hickman
Sectors:
Industries:
Analyst Ranking
Top 28%
#1447 out of 5290 analysts
Average Return
+11.76%
Win Rate
57%12 out of 21
Risk vs Reward
Poor
Good
Eddie Hickman's 5 best and worst ratings
| Name / Ticker | Gain/Loss | Entry Price | Exit Price | Period | Rating |
|---|---|---|---|---|---|
Iveric Bio IncISEE | +167.40% | $14.94 | $39.95 | 2022-09-06 - 2023-07-10 | Strong Buy |
Tarsus Pharmaceuticals IncTARS | +85.16% | $16.98 | $31.44 | 2023-09-10 - 2024-09-10 | Strong Buy |
Tarsus Pharmaceuticals IncTARS | +70.70% | $42.56 | $72.65 | 2025-02-25 - 2026-02-25 | Strong Buy |
Tarsus Pharmaceuticals IncTARS | +67.37% | $18.51 | $30.98 | 2023-06-15 - 2024-06-14 | Strong Buy |
Tarsus Pharmaceuticals IncTARS | +57.10% | $16.83 | $26.44 | 2023-08-13 - 2024-08-13 | Strong Buy |
Eddie Hickman Analyst Color
Get additional color on Eddie Hickman's coverage of popular stocks
3 months ago
TARS
6 months ago
HELP
a year ago
ZVRA
Eddie Hickman's Stock Coverage
| Name / Ticker | No. Ratings | Rating | Price Target | Upside/Downside | Action | Date |
|---|---|---|---|---|---|---|
Zevra Therapeutics IncZVRA | 2 | Strong Buy | $25.00 | +123.81% | Maintains | a month ago |
Ataibeckley IncATAI | 2 | Strong Buy | $16.00 | +255.56% | Maintains | 2 months ago |
Tarsus Pharmaceuticals IncTARS | 7 | Strong Buy | $90.00 | +49.15% | Maintains | 3 months ago |
Promis Neurosciences IncPMN | 3 | Strong Buy | $35.00 | +259.71% | Maintains | 4 months ago |
Cybin IncHELP | 2 | Strong Buy | $48.00 | +983.52% | Maintains | 6 months ago |
Gh Research PLCGHRS | 1 | Strong Buy | $32.00 | N/A | Initiates Coverage On | a year ago |
Outlook Therapeutics IncOTLK | 3 | Strong Buy | $12.00 | N/A | Reiterates | a year ago |
Iveric Bio IncISEE | 1 | Strong Buy | $35.00 | N/A | Maintains | 4 years ago |
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.